Hungarian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
aclarubicin/nausea
A hivatkozás a vágólapra kerül
Oldal 1 tól től 20 eredmények
Aclarubicin: experimental and clinical experience.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Aclarubicin, discovered by Umezawa in 1975, is a new cytostatic anthracycline antibiotic. It is one of the anthracyclines with the lowest cardiotoxicity, it is not mutagenic and it stimulates differentiation of tumour cells. The therapeutic index of aclarubicin (efficacy related to toxicity) is
An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
We evaluated the efficacy and toxicity of aclarubicin for acute non-lymphocytic leukemia (ANLL) refractory to daunorubicin in childhood. Twenty-four patients were treated with aclarubicin and prednisolone with or without 6-mercaptopurine and behenoyl-cytosine arabinoside daily for 5 to 14 days. Of
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
In order to develop new strategies for the treatment of relapsed or refractory acute myeloid leukemia, the German AML Cooperative Group performed a prospective multicenter phase II study to evaluate the antileukemic efficacy of aclarubicin 60 mg/m2/day and etoposide 100 mg/m2/day each given for 5
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
A comparative trial of a combination of daunorubicin and cytosine arabinoside (Regimen A) and a combination of aclarubicin and cytosine arabinoside (Regimen B) was performed. Sixteen patients with acute non-lymphocytic leukemia, previously untreated, were entered into this study. Five of 8 patients
Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12
Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Aclarubicin, a new anthracycline antibiotic, was used to treat 24 adult patients with refractory adult leukemia, using a total dose of 300 mg/m2 (75 mg/m2/day X 4). There were 20 patients with acute myelogenous and four with acute lymphoblastic leukemia. Approximately two-thirds of the patients had
Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Forty patients with relapsing acute leukaemias were treated with aclacinomycin A (aclarubicin, ACM), 25 mg/m2 i.v. daily for 7 days. Twenty-nine patients with acute myeloid (AML) and five with acute lymphoblastic (ALL) leukaemia were evaluable. The overall response rate was 29.5%. Eight complete
Phase II study of aclarubicin in acute myeloblastic leukemia.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Aclarubicin is a new anthracycline antibiotic that produces substantially less cardiotoxicity in animals that does doxorubicin. Based upon prior Phase I and II trials in leukemia, a Phase II study in acute myeloblastic leukemia was developed to assess the response rate and toxicity in previously
[Combined chemotherapy with cisplatin and aclarubicin hydrochloride for metastatic brain tumors].
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Thirteen patients with metastatic brain tumors were treated by combined chemotherapy with cisplatin and aclarubicin hydrochloride. Initial response to this therapy was evaluated by the changes of tumor size on CT scan and clinical state during and after the treatment. The side effects and the causes
[A clinical study of the radiosensitization of aclarubicin].
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Sixty six patients with an advanced or a relapsed cancer have been treated with a combination of radiation and aclarubicin (ACR). The average irradiation dose was 45 +/- 15 Gy, and the combined total dose of ACR ranged from 130 to 260 mg, depending upon the following differing schedules: 10 mg x 3
Aclarubicin in the treatment of multiple myeloma.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Fourteen patients with multiple myeloma received aclarubicin (ACR) intravenous drip infusion at a dose of 15-25 mg/m2/day for 7 days every 3 weeks. Nine of the patients achieved more than a 25% reduction in M-protein. In two of the nine the reduction was more than 50% and the duration of their
Aclarubicin in the treatment of elderly patients with acute nonlymphocytic leukemia.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Thirteen previously untreated patients aged 70 and above with acute nonlymphocytic leukemia were treated with aclarubicin (ACR) alone. Among 10 cases (3, acute myelocytic leukemia; 4, acute myelomonocytic leukemia; 2, acute monocytic leukemia; and one, acute erythroleukemia) in which an evaluation
[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
The clinical efficacy of aclarubicin, an anthracycline antibiotic, was studied in 48 patients with leukemia. The antibiotic was used in the following combinations with cytarabine: "7 + 7", "5 + 5" and "7 & 3". A complete remission was stated in 14 (42.4 per cent) out of 33 patients with acute
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Elderly patients with acute myelomonocytic leukaemia (AMMoL) frequently have a poor quality of life after induction of remission using high-intensity treatment; we seek a more appropriate regimen for such patients. An 86-year-old man was hospitalized with a diagnosis of AMMoL (FAB classification
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
Aclarubicin (ACR) was administered in a prospective cooperative phase II trial to 44 patients with possibly refractory acute nonlymphocytic leukemia who were previously treated with daunorubicin and cytarabine. Induction treatment consisted of 80 mg/m2 of ACR iv daily for 3 days, followed by 80
A legteljesebb gyógynövény-adatbázis, amelyet a tudomány támogat
- Működik 55 nyelven
- A tudomány által támogatott gyógynövényes kúrák
- Gyógynövények felismerése kép alapján
- Interaktív GPS térkép - jelölje meg a gyógynövényeket a helyszínen (hamarosan)
- Olvassa el a keresésével kapcsolatos tudományos publikációkat
- Keresse meg a gyógynövényeket hatásuk szerint
- Szervezze meg érdeklődését, és naprakész legyen a hírkutatással, a klinikai vizsgálatokkal és a szabadalmakkal
Írjon be egy tünetet vagy betegséget, és olvassa el azokat a gyógynövényeket, amelyek segíthetnek, beírhat egy gyógynövényt, és megtekintheti azokat a betegségeket és tüneteket, amelyek ellen használják.
* Minden információ publikált tudományos kutatáson alapul
